RTP Mobile Logo
The New Biology of Non-Small Cell Lung Cancer
Released October 2015

Featuring perspectives from Dr Heather Wakelee. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical oncologists and other healthcare providers involved in the treatment of lung cancer.

    OVERVIEW OF ACTIVITY
    Lung cancer is a devastating disease with a broad-reaching impact on public health, accounting for 14% of all new cancer cases in the US and the most cancer-related deaths among both men and women. In the year 2015, it is estimated that 221,200 individuals will be diagnosed and 158,040 individuals will die from the disease. Importantly, despite the many advances over the past few decades related to surgery, radiation therapy and chemotherapy, death rates attributable to lung cancer have remained relatively unchanged. Today, many are optimistic that these trends have already started to change as recent research advances have led to an explosion in lung cancer genetic and biologic knowledge among scientists and clinicians working in this area of cancer medicine.

    To bridge the gap between research and patient care, this video presentation by Dr Heather Wakelee uses a review of recent relevant publications and presentations, ongoing clinical trials and clinical investigator treatment preferences to assist medical oncologists and other healthcare providers involved in the treatment of lung cancer with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Discriminate among molecular determinates that may be used to refine non-small cell lung cancer (NSCLC) prognosis and/or predict therapeutic response to an individual treatment.
    • Employ an understanding of personalized medicine to individualize the use of available EGFR inhibitors in the treatment of NSCLC.
    • Describe mechanisms of tumor resistance to EGFR tyrosine kinase inhibitors (TKIs), and identify investigational therapeutic opportunities to circumvent these processes.
    • Communicate the efficacy and safety of crizotinib, ceritinib (LDK378) and other investigational ALK inhibitors to appropriate patients with NSCLC, considering the predictive utility of ALK mutation testing.
    • Describe emerging data on the efficacy and safety of tumor immunotherapy directed at the PD-1/PD-L1 pathway in lung cancer, and consider this information when counseling patients regarding clinical trial participation.
    • Recognize the results of recently completed Phase III trials examining the efficacy and safety of the novel monoclonal antibodies necitumumab and ramucirumab for patients with advanced NSCLC.
    • Assess new oncogenic pathways mediating the growth of unique NSCLC tumor subsets, and recall emerging data with experimental agents exploiting these targets.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Presenting Faculty Member

    Heather Wakelee, MD
    Associate Professor of Medicine
    Division of Oncology
    Stanford University School of Medicine
    Stanford Cancer Institute
    Stanford, California

    Consulting Agreement: Peregrine Pharmaceuticals Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Genentech BioOncology, Lilly, MedImmune Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Xcovery; Grants: AstraZeneca Pharmaceuticals LP, Clovis Oncology, MedImmune Inc, Xcovery.

    Project Steering Committee Members

    D Ross Camidge, MD, PhD
    Director, Thoracic Oncology Clinical Program
    Associate Director for Clinical Research
    University of Colorado Cancer Center
    Aurora, Colorado

    Advisory Committee: ARIAD Pharmaceuticals Inc, Astex Pharmaceuticals, Clarient Inc, Exelixis Inc, Genentech BioOncology, ImmunoGen Inc, IndiPharm, Lilly, Servier; Contracted Research and Honoraria: ARIAD Pharmaceuticals Inc.

    Leora Horn, MD, MSc
    Associate Professor of Medicine
    Assistant Director, Educator Development Program
    Vanderbilt University Medical Center
    Nashville, Tennessee

    Advisory Committee: Bristol-Myers Squibb Company, Clovis Oncology, Helix BioPharma Corp, Puma Biotechnology Inc; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Merck; Contracted Research: Astellas Pharma Global Development Inc; Honoraria: Boehringer Ingelheim Pharmaceuticals Inc.

    Nathan A Pennell, MD, PhD
    Assistant Professor, Hematology and Medical Oncology
    Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
    Director, Cleveland Clinic Lung Cancer Medical Oncology Program
    Cleveland, Ohio

    No real or apparent conflicts of interest to disclose.

    Suresh S Ramalingam, MD
    Professor of Hematology and Medical Oncology
    Director, Division of Medical Oncology
    Emory University
    Winship Cancer Institute
    Atlanta, Georgia

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, EMD Serono Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Merck, Novartis Pharmaceuticals Corporation.

    Gregory J Riely, MD, PhD
    Associate Attending
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreement: Novartis Pharmaceuticals Corporation; Contracted Research: GlaxoSmithKline, Infinity Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology.

    Lecia V Sequist, MD, MPH
    Associate Professor of Medicine
    Harvard Medical School
    Center for Thoracic Cancers
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Genentech BioOncology, Merrimack Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Taiho Oncology Inc.

    David R Spigel, MD
    Program Director, Lung Cancer Research
    Sarah Cannon Research Institute
    Nashville, Tennessee

    No real or apparent conflicts of interest to disclose.

    PROJECT CHAIRDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas Pharma Global Development Inc, Foundation Medicine, Genentech BioOncology, Lilly and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: October 2015
    Expiration date: October 2016

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
Chapters:
00:00:01 - Introduction
00:01:32 - EGFR mutation-positive disease 
00:15:33 - ALK/EML4 translocation 
00:21:22 - Immunotherapy 
00:31:57 - New directions in targeted therapy